BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
IVDs on the rise
Radiopharmaceuticals
Science '22 in Review
Top Biopharma Trends of 2022
Top Med-tech Trends of 2022
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Monday, October 2, 2023
See today's BioWorld
Home
» Zelira’s stock triples as cannabinoid outperforms Lyrica in pain
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Zelira’s stock triples as cannabinoid outperforms Lyrica in pain
May 31, 2023
By
Tamra Sami
No Comments
Medicinal cannabis company Zelira Therapeutics Ltd.’s stock shot up 224% on May 31 on the heels of news that its cannabinoid product, ZLT-L-007, outperformed Lyrica (pregabalin, Pfizer Inc) in a head-to-head trial in diabetic nerve pain.
BioWorld
Clinical
Neurology/Psychiatric
Australia